What is Merck & Co.'s payments to acquire global rights?

Merck & Co. (MRK) reported payments to acquire global rights of $0.00 in Q4 2025.

How has Merck & Co.'s payments to acquire global rights changed year-over-year?

Merck & Co.'s payments to acquire global rights decreased by 100.0% year-over-year, from $175.00M to $0.00.

What does payments to acquire global rights mean?

Cash paid to obtain rights to sell or develop third-party products.

Investing

Payments to Acquire Global Rights

Year-over-year, this metric declined by 100.0%, from $175.00M to $0.00.

Analysis

StatementCash Flow Statement

SectionInvesting

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ1 2022

Last reportedQ4 2025

How to read this metric

Increased spending suggests a reliance on external innovation to bolster the product pipeline, whereas lower spending may indicate a strong internal R&D output.

Detailed definition

Cash outlays specifically directed toward securing intellectual property, licensing, or global commercialization rights...

Peer comparison

Standard in the pharmaceutical industry where licensing deals are a primary growth lever.

Metric ID: cf_mrk_payments_to_acquire_global_rights

Historical Data

4 years

	FY'22	FY'23	FY'24	FY'25
Value	$0.00	$0.00	$700.00M	$0.00
YoY Change	—	—	—	-100.0%

Range$0.00 – $700.00M

Avg YoY Growth-100.0%

Median YoY Growth-100.0%

Frequently Asked Questions

What is Merck & Co.'s payments to acquire global rights?: Merck & Co. (MRK) reported payments to acquire global rights of $0.00 in Q4 2025.
How has Merck & Co.'s payments to acquire global rights changed year-over-year?: Merck & Co.'s payments to acquire global rights decreased by 100.0% year-over-year, from $175.00M to $0.00.
What does payments to acquire global rights mean?: Cash paid to obtain rights to sell or develop third-party products.